{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:31:04Z","timestamp":1793845864687,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304282"],"award-info":[{"award-number":["82304282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117932","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:14:49Z","timestamp":1751714089000},"page":"117932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy"],"prefix":"10.1016","volume":"297","author":[{"given":"Haoyu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-680X","authenticated-orcid":false,"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117932_bib1","doi-asserted-by":"crossref","first-page":"E579","DOI":"10.1152\/ajpendo.00033.2020","article-title":"Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice","volume":"318","author":"Cavallari","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2025.117932_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650403","article-title":"RIPK2 as a new therapeutic target in inflammatory bowel diseases","volume":"12","author":"Honjo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117932_bib3","doi-asserted-by":"crossref","first-page":"14391","DOI":"10.1021\/acs.jmedchem.3c00593","article-title":"Receptor interacting ser\/thr-protein kinase 2 as a new therapeutic target","volume":"66","author":"Rivoal","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fcell.2019.00208","article-title":"NOD signaling and cell death","volume":"7","author":"Heim","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117932_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.1104911","article-title":"Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract","volume":"307","author":"Kobayashi","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117932_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd2783","article-title":"Unleashing the therapeutic potential of NOD-like receptors","volume":"8","author":"Geddes","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117932_bib7","doi-asserted-by":"crossref","first-page":"34057","DOI":"10.18632\/oncotarget.6106","article-title":"Targeting RIPK1,2,3 to combat inflammation","volume":"6","author":"Bullock","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117932_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neulet.2018.01.057","article-title":"NOD2-RIP2 contributes to the inflammatory responses of mice in vivo to Streptococcus pneumoniae","volume":"671","author":"Zheng","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2025.117932_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41590-018-0188-x","article-title":"RIP kinases as modulators of inflammation and immunity","volume":"19","author":"He","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2025.117932_bib10","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1038\/s41467-018-06451-3","article-title":"RIP2 filament formation is required for NOD2 dependent NF-kappaB signalling","volume":"9","author":"Pellegrini","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117932_bib11","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/ncomms7442","article-title":"A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production","volume":"6","author":"Nachbur","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117932_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/molecules23020453","article-title":"Identification of novel protein kinase receptor type 2 inhibitors using pharmacophore and structure-based virtual screening","volume":"23","author":"Cruz","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117932_bib13","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/acs.jmedchem.2c00604","article-title":"Discovery of potent and selective receptor-interacting serine\/threonine protein kinase 2 (RIPK2) inhibitors for the treatment of inflammatory bowel diseases (IBDs)","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib14","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1021\/acs.jmedchem.1c01118","article-title":"Optimization of a series of RIPK2 PROTACs","author":"Miah","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib15","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib16","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1021\/acs.jmedchem.6b00211","article-title":"The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase","volume":"59","author":"Haile","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib17","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1021\/acs.jmedchem.9b00575","article-title":"Discovery of a first-in-class receptor interacting protein 2 (RIP2) kinase specific clinical candidate, 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases","volume":"62","author":"Haile","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib18","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acsmedchemlett.9b00141","article-title":"Discovery of pyrazolocarboxamides as potent and selective receptor interacting protein 2 (RIP2) kinase inhibitors","volume":"10","author":"Haffner","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117932_bib19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/acsmedchemlett.8b00344","article-title":"Identification of quinoline-based RIP2 kinase inhibitors with an improved therapeutic index to the hERG ion channel","volume":"9","author":"Haile","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117932_bib20","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/acsmedchemlett.7b00258","article-title":"Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases","volume":"8","author":"He","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117932_bib21","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1021\/acsmedchemlett.0c00591","article-title":"Novel thienopyridines as RIPK2 inhibitors for treating inflammatory bowel disease","volume":"11","author":"Sabnis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117932_bib22","doi-asserted-by":"crossref","first-page":"G500","DOI":"10.1152\/ajpgi.00163.2021","article-title":"The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease","volume":"321","author":"Ermann","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejmech.2025.117932_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/cancers10060184","article-title":"RIPK2: new elements in modulating inflammatory breast cancer pathogenesis","volume":"10","author":"Zare","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117932_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-23-0584","article-title":"Receptor-interacting protein kinase 2 is an immunotherapy target in pancreatic cancer","volume":"14","author":"Sang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117932_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.yexcr.2009.12.001","article-title":"RIP2: a novel player in the regulation of keratinocyte proliferation and cutaneous wound repair?","volume":"316","author":"Adams","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2025.117932_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/JLB.3CE0718-293","article-title":"Allergic asthma: RIPK2 takes the lead","volume":"104","author":"Poudel","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2025.117932_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cld.2019.09.005","article-title":"Acute liver failure secondary to drug-induced liver injury","volume":"24","author":"Chayanupatkul","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.ejmech.2025.117932_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3727\/105221617X15084371374138","article-title":"Acetaminophen toxicity: novel insights into mechanisms and future perspectives","volume":"18","author":"Ramachandran","year":"2018","journal-title":"Gene Expr."},{"key":"10.1016\/j.ejmech.2025.117932_bib29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/cpt.1701","article-title":"Acetaminophen-induced liver damage in hepatic steatosis","volume":"107","author":"Garc\u00eda-Rom\u00e1n","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117932_bib30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jhep.2017.07.005","article-title":"Acetaminophen (APAP) hepatotoxicity\u2014Isn\u2019t it time for APAP to go away?","volume":"67","author":"Lee","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.117932_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0039-1679919","article-title":"Acetaminophen hepatotoxicity","volume":"39","author":"Ramachandran","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.ejmech.2025.117932_bib32","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00204-018-2237-5","article-title":"Autophagy and acetaminophen-induced hepatotoxicity","volume":"92","author":"Shan","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2025.117932_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/sjg.sjg_406_21","article-title":"N-acetylcysteine for non-acetaminophen induced acute liver failure: a review","volume":"28","author":"Jiang","year":"2022","journal-title":"Saudi J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.117932_bib34","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-016-0606-z","article-title":"Olmutinib: first global approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117932_bib35","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib36","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/jm2009327","article-title":"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer","volume":"54","author":"Sutherlin","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib37","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1021\/acs.jmedchem.8b01391","article-title":"Design, synthesis, and biological evaluation of 6-substituted thieno[3,2-d]pyrimidine analogues as dual epidermal growth factor receptor kinase and microtubule inhibitors","volume":"62","author":"Romagnoli","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib38","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1021\/acs.jmedchem.4c02478","article-title":"Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as the first bifunctional PI3K\u03b4 isoform selective\/bromodomain and extra-eerminal inhibitors","volume":"68","author":"Ran","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116649","article-title":"Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy","volume":"276","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115955","article-title":"Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7","volume":"263","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib41","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1021\/acs.jmedchem.1c00459","article-title":"Identification of thieno[3,2-d]pyrimidine derivatives as dual inhibitors of focal adhesion kinase and FMS-like tyrosine kinase 3","volume":"64","author":"Cho","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117308","article-title":"Identification of thieno[3,2-d]pyrimidine derivatives as potent and selective janus kinase 1 inhibitors","volume":"286","author":"Kim","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117932_bib43","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/bioinformatics\/btq584","article-title":"The SMARTCyp cytochrome P450 metabolism prediction server","volume":"26","author":"Rydberg","year":"2010","journal-title":"Bioinformatics"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500697X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500697X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:56:40Z","timestamp":1776920200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500697X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"alternative-id":["S022352342500697X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117932","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117932"}}